利瓦罗克萨班和诺普拉桑联合使用的关键考虑:揭示潜在的药物动力学相互作用
Xiao-Yu Xu1, Zhe-Yan Zhang1, Xiao-Dan Zhang1
1School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, PR China.
诺普拉桑药物通过影响CYP2J2酶活性来抑制里瓦罗克萨班代谢. 这种相互作用会影响利瓦洛克萨班.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药物新陈代谢 药物新陈代谢
- 药物遗传学 药物遗传学
背景情况:
- 里瓦罗克萨班是一种广泛使用的抗凝剂.
- 了解它的新陈代谢和药物相互作用对于安全有效的使用至关重要.
- CYP2J2是参与里瓦洛克萨班代谢的关键酶.
研究的目的:
- 调查代谢酶抑制和遗传多态性对利瓦洛克萨班药理动力学和药理动力学的影响.
- 为了探索vonoprazan和rivaroxaban之间的相互作用.
- 阐明CYP2J2基因变异在里瓦洛克萨班代谢中的作用.
主要方法:
- 在体外酶分析以选抑制剂.
- UPLC-MS/MS用于量化里瓦罗克萨班及其代谢物M2-1.
- 在生体内对大鼠进行的药理动力学研究.
- 使用人类重组CYP2J2百科索姆的酶动力学.
主要成果:
- 抑制酸性药物,特别是诺普拉桑,在体外显著抑制了里瓦罗克萨班代谢.
- 诺普拉赞增加了里瓦罗克萨班的全身暴露,并在体内延长了前列血时间.
- CYP2J2遗传多态性影响了里瓦罗克萨班代谢和诺普拉桑的抑制作用.
- 诺普拉桑和里瓦罗克萨班与CYP2J2之间的竞争性结合被提出为机制.
结论:
- 诺普拉桑抑制CYP2J2,影响里瓦罗克萨班的药理动力学和药理动力学.
- CYP2J2遗传变异调节了这种药物相互作用的程度.
- 这些发现支持基于CYP2J2基因型的个性化里瓦洛克萨班管理.
更多相关视频
08:28Microsurgical Skills of Establishing Permanent Jugular Vein Cannulation in Rats for Serial Blood Sampling of Orally Administered Drug
Published on: December 14, 2021
07:13Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
Published on: May 24, 2024
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Factors Affecting Renal Clearance: Drug Distribution and Drug Interactions
One important factor is the relationship between renal clearance and the apparent volume of distribution. Renal clearance tends to be inversely proportional to the apparent volume of distribution. Drugs with an extensive distribution volume or those...
Factors Affecting Protein-Drug Binding: Drug Interactions
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Factors Affecting Protein-Drug Binding: Patient-Related Factors
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
